Phase I study of gefitinib, irinotecan, 5-fluorouracil and leucovorin in patients with metastatic colorectal cancer

JA Meyerhardt, JW Clark, JG Supko, JP Eder… - Cancer chemotherapy …, 2007 - Springer
… between gefitinib and irinotecan [18–21]. We therefore conducted a phase I study combining
gefitinib with bolus 5-fluorouracil (5-FU), irinotecan, and leucovorin (IFL) in patients with …

A phase II study of gefitinib, 5-fluorouracil, leucovorin, and oxaliplatin in previously untreated patients with metastatic colorectal cancer

GA Fisher, T Kuo, M Ramsey, E Schwartz… - Clinical Cancer …, 2008 - AACR
… of irinotecan or oxaliplatin with 5-fluorouracilphase I study using this regimen as well as a
phase II study with this regimen in previously treated patients with metastatic colorectal cancer

[HTML][HTML] A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and irinotecan in patients with colorectal cancer

ML Veronese, W Sun, B Giantonio, J Berlin… - … journal of cancer, 2005 - nature.com
irinotecan, dose reduction was required. We propose that the interaction of irinotecan and
gefitinib in our trial … in greater than anticipated exposure to irinotecan and its active metabolite. …

Phase I study of gefitinib, oxaliplatin, 5-fluorouracil, and leucovorin (IFOX) in patients with advanced solid malignancies

CD Cho, GA Fisher, J Halsey, BI Sikic - Investigational new drugs, 2006 - Springer
Phase I study of FOLFOX plus gefitinib because of the high frequency of EGFR expression
in colorectal cancers … to combine this agent with oxaliplatin rather than irinotecan [4, 15]. This …

Gefitinib in combination with oxaliplatin and 5-fluorouracil in irinotecan-refractory patients with colorectal cancer: a phase I study of the arbeits gemeinschaft …

JT Hartmann, JP Pintoffl, H Kröning… - Oncology Research …, 2008 - karger.com
… BI: Phase II study of gefitinib, fluorouracil, leucovorin, and … previously treated patients
with metastatic colorectal cancer. … and leucovorin: an active regimen for first-line metastatic

[HTML][HTML] Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I–II study

I Chau, D Cunningham, T Hickish, A Massey… - Annals of oncology, 2007 - Elsevier
… In this study, the DLTs of irinotecan and gefitinib in combination were diarrhoea and
neutropenia… When irinotecan, infused 5-FU and leucovorin (FOLFIRI) was combined with erlotinib …

[HTML][HTML] A phase II study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study)

J Stebbing, M Harrison, R Glynne-Jones… - … journal of cancer, 2008 - nature.com
… of phase I and II studies in metastatic colorectal carcinoma … effects of gefitinib in combination
with standard 5-fluorouracil (5-… a recent study combining gefitinib and irinotecan in patients

Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin-refractory colorectal cancer: a phase I/II study of the …

RD Hofheinz, S Kubicka, J Wollert, D Arnold… - Oncology Research …, 2006 - karger.com
… L, Haller DG, O’Dwyer PD: A phase II trial of gefitinib with 5-fluorouracil, leucovorin, and
irinotecan in patients with colorectal cancer. Br J Cancer 2005;92:1846–1849. 12 Rothenberg M, …

Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774) Early Termination Due To Increased Toxicities

WA Messersmith, DA Laheru, NN Senzer… - Clinical cancer …, 2004 - AACR
colorectal cancer. A response rate of 78% has been reported in a phase II study combining
gefitinib with … when combined with irinotecan in patients with irotecan-resistant colorectal

[HTML][HTML] … and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic …

G Folprecht, MP Lutz, P Schöffski, T Seufferlein… - Annals of …, 2006 - Elsevier
… kinase inhibitors, like gefitinib, that are … study, a phase III program has been started that
investigates the addition of cetuximab to irinotecan plus infusional 5-FU/FA (ie CRYSTAL study